论文部分内容阅读
目的:研究对比胺多西他赛联合表柔比星新辅助化疗治疗局部晚期乳腺癌的临床效果。方法:选取在我院接受治疗的72例局部晚期乳腺癌的患者,将其分为两组,治疗组采用多西他赛联合表柔比星新辅助化疗治疗,对照组给予5-氟尿嘧啶(5-FU)联合EPI、环磷酰胺(CTX)进行治疗,观察两组的治疗效果和不良反应的发生情况。结果:治疗组患者在治疗后的总有效率97.56%明显高于对照组的总有效率85.36%,对比后两组差异显著(P<0.05),且治疗组患者的不良反应的发生率与对照组相比差异无统计学意义(P>0.05)。结论:多西他赛联合表柔比星新辅助化疗治疗局部晚期乳腺癌具有比较明显的效果,不良反应的发生较少,预后较好,值得临床推广使用。
OBJECTIVE: To study the clinical efficacy of amiodaril in combination with epirubicin neoadjuvant chemotherapy in the treatment of locally advanced breast cancer. Methods: A total of 72 patients with locally advanced breast cancer who were treated in our hospital were divided into two groups: the treatment group received docetaxel plus epirubicin neoadjuvant chemotherapy, and the control group received 5-fluorouracil -FU) combined with EPI, cyclophosphamide (CTX) for treatment, the treatment of two groups were observed and the incidence of adverse reactions. Results: The total effective rate of the treatment group after treatment was 97.56%, which was significantly higher than that of the control group (85.36%). There was significant difference between the two groups (P <0.05), and the incidence of adverse reactions in the treatment group was significantly higher than that of the control group There was no significant difference between the two groups (P> 0.05). Conclusion: Docetaxel combined with epirubicin neoadjuvant chemotherapy has obvious effect on locally advanced breast cancer with fewer adverse reactions and better prognosis, which is worthy of clinical application.